Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene

J. Alexander Bodkin, Michael J. Coleman, Laura J. Godfrey, Claudia M.B. Carvalho, Charity J. Morgan, Raymond F. Suckow, Thea Anderson, Dost Öngür, Marc J. Kaufman, Kathryn E. Lewandowski, Arthur J. Siegel, Elliot Waldstreicher, Christopher M. Grochowski, Daniel C. Javitt, Dan Rujescu, Scott Hebbring, Richard Weinshilboum, Stephanie Burgos Rodriguez, Colette Kirchhoff, Timothy VisscherAlexander Vuckovic, Allison Fialkowski, Shane McCarthy, Dheeraj Malhotra, Jonathan Sebat, Donald C. Goff, James I. Hudson, James R. Lupski, Joseph T. Coyle, Uwe Rudolph, Deborah L. Levy

Research output: Contribution to journalArticle

Abstract

Background: The increased mutational burden for rare structural genomic variants in schizophrenia and other neurodevelopmental disorders has so far not yielded therapies targeting the biological effects of specific mutations. We identified two carriers (mother and son) of a triplication of the gene encoding glycine decarboxylase, GLDC, presumably resulting in reduced availability of the N-methyl-D-aspartate receptor coagonists glycine and D-serine and N-methyl-D-aspartate receptor hypofunction. Both carriers had a diagnosis of a psychotic disorder. Methods: We carried out two double-blind, placebo-controlled clinical trials of N-methyl-D-aspartate receptor augmentation of psychotropic drug treatment in these two individuals. Glycine was used in the first clinical trial, and D-cycloserine was used in the second one. Results: Glycine or D-cycloserine augmentation of psychotropic drug treatment each improved psychotic and mood symptoms in placebo-controlled trials. Conclusions: These results provide two independent proof-of-principle demonstrations of symptom relief by targeting a specific genotype and explicitly link an individual mutation to the pathophysiology of psychosis and treatment response.

Original languageEnglish (US)
Pages (from-to)523-535
Number of pages13
JournalBiological Psychiatry
Volume86
Issue number7
DOIs
StatePublished - Oct 1 2019
Externally publishedYes

Keywords

  • Bipolar disorder
  • Copy number variant
  • Genetics
  • Glycine decarboxylase
  • NMDAR hypofunction
  • Schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene'. Together they form a unique fingerprint.

  • Cite this

    Bodkin, J. A., Coleman, M. J., Godfrey, L. J., Carvalho, C. M. B., Morgan, C. J., Suckow, R. F., Anderson, T., Öngür, D., Kaufman, M. J., Lewandowski, K. E., Siegel, A. J., Waldstreicher, E., Grochowski, C. M., Javitt, D. C., Rujescu, D., Hebbring, S., Weinshilboum, R., Rodriguez, S. B., Kirchhoff, C., ... Levy, D. L. (2019). Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. Biological Psychiatry, 86(7), 523-535. https://doi.org/10.1016/j.biopsych.2019.04.031